INNATE PHARMA : preclinical data opening new perspectives for development ... GlobeNewswire (press release) Furthermore, the new data showed that in combination with the anti-CD20 antibody rituximab*, lirilumab enhanced NK cell-mediated, antibody-dependent cellular cytotoxicity (ADCC) against lymphoma in vitro and in vivo in mouse models. Taken together ... |
